Niagen Bioscience, Inc. (NAGE) stock
NAGENasdaqMedicinal Chemicals & Botanical ProductsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 4, 2026Score 14/3013% below fair value
$2.01−0.06 (-2.66%)
Close on Nov 16, 2026Market cap $159.04MP/E 16.8Yield –
Niagen Bioscience enterprise value
Enterprise value is market cap plus debt, minus cash: the value of the whole business to all its investors.
Niagen Bioscience's enterprise value was $98.57M on Nov 11, 2026, against $474.87M a year earlier. Over the last 5 years it ranged from $66.76M to $1.07B, with a median of $179.86M.
Enterprise Value at the end of each year
| Period | Period end | Value | Change |
|---|---|---|---|
| 2026 | Nov 11, 2026 | $98.57M | -77.7% |
| 2025 | Dec 31, 2025 | $442.21M | +19.2% |
| 2024 | Dec 31, 2024 | $370.93M | +361.6% |
| 2023 | Dec 29, 2023 | $80.35M | -20.7% |
| 2022 | Dec 30, 2022 | $101.26M | -54.3% |
| 2021 | Dec 31, 2021 | $221.57M | – |
| 2020 | Dec 31, 2020 | -$15.18M | – |
| 2019 | Dec 31, 2019 | -$18.62M | – |
| 2018 | Dec 31, 2018 | -$28.03M | -110.9% |
| 2017 | Dec 29, 2017 | $256.18M | +110.0% |
| 2016 | Dec 30, 2016 | $122.00M | -5.1% |
| 2015 | Dec 31, 2015 | $128.60M | +41.5% |
| 2014 | Dec 31, 2014 | $90.87M | -34.9% |
| 2013 | Dec 31, 2013 | $139.68M | +195.1% |
| 2012 | Dec 31, 2012 | $47.34M | +24.4% |
| 2011 | Dec 30, 2011 | $38.05M | – |
See a number that looks wrong?